JNJ-Q2

JNJ-Q2

File:JNJ-Q2.svg
Systematic (IUPAC) name
7-[(3E)-3-(2-Amino-1-fluoroethylidene)-1-piperidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
Clinical data
Routes of administration	Oral, IV
Identifiers
ChemSpider	9721013 N
Chemical data
Formula	C21H23F2N3O4
Molecular mass	419.42 g/mol
SMILES Fc1c(c(OC)c2c(c1)C(=O)C(\C(=O)O)=C/N2C3CC3)N4C/C(=C(/F)CN)CCC4
InChI InChI=InChI=1S/C21H23F2N3O4/c1-30-20-17-13(19(27)14(21(28)29)10-26(17)12-4-5-12)7-15(22)18(20)25-6-2-3-11(9-25)16(23)8-24/h7,10,12H,2-6,8-9,24H2,1H3,(H,28,29)/b16-11+ N Key:VMKVDAAFMQKZJS-LFIBNONCSA-N N

JNJ-Q2 is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia. Specifically, JNJ-Q2 is being actively studied for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections.

Furiex Pharmaceuticals has licensed JNJ-Q2 from Janssen Pharmaceutica, a unit of Johnson & Johnson, which discovered JNJ-Q2. Furiex is responsible for its development and commercialization. Both oral and intravenous formulations are being developed.